
CorMedix Inc (NASDAQ:CRMD – Free Report) – HC Wainwright cut their FY2026 earnings estimates for CorMedix in a research report issued on Friday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.38 per share for the year, down from their previous forecast of $0.54. The consensus estimate for CorMedix’s current full-year earnings is $0.44 per share. HC Wainwright also issued estimates for CorMedix’s Q4 2026 earnings at ($0.13) EPS, FY2029 earnings at $0.73 EPS and FY2030 earnings at $0.97 EPS.
Other equities analysts have also issued research reports about the stock. Needham & Company LLC increased their target price on shares of CorMedix from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. UBS Group set a $19.00 price target on shares of CorMedix in a research report on Tuesday, November 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $13.00 price target (down from $15.00) on shares of CorMedix in a research note on Friday, November 13th. Royal Bank Of Canada increased their price objective on shares of CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Tuesday, November 10th. Finally, Wall Street Zen lowered shares of CorMedix from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.22.
CorMedix Stock Down 3.6%
Shares of CorMedix stock opened at $4.50 on Tuesday. CorMedix has a twelve month low of $4.49 and a twelve month high of $13.02. The stock has a market capitalization of $357.93 million, a price-to-earnings ratio of 3.62, a PEG ratio of 1.07 and a beta of 1.48. The company has a current ratio of 2.43, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. The business’s 50 day simple moving average is $6.96 and its 200-day simple moving average is $7.52.
CorMedix (NASDAQ:CRMD – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 26.70%. The firm had revenue of $54.52 million during the quarter, compared to analysts’ expectations of $51.76 million.
Institutional Trading of CorMedix
A number of institutional investors and hedge funds have recently modified their holdings of CRMD. BlackRock Inc. bought a new stake in shares of CorMedix in the second quarter valued at about $49,644,000. Goldman Sachs Group Inc. increased its stake in CorMedix by 167.9% during the third quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company’s stock valued at $9,620,000 after acquiring an additional 782,989 shares during the period. Marshall Wace LLP increased its stake in CorMedix by 53.4% during the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company’s stock valued at $9,205,000 after acquiring an additional 415,887 shares during the period. Pacer Advisors Inc. increased its stake in CorMedix by 128.7% during the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock valued at $3,942,000 after acquiring an additional 326,724 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in CorMedix by 150.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company’s stock valued at $3,443,000 after acquiring an additional 263,618 shares in the last quarter. 34.18% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at CorMedix
In related news, Director Myron Kaplan purchased 25,000 shares of the stock in a transaction dated Monday, November 16th. The shares were acquired at an average cost of $4.88 per share, for a total transaction of $122,000.00. Following the acquisition, the director directly owned 256,487 shares in the company, valued at approximately $1,251,656.56. The trade was a 10.80% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Joseph Todisco bought 80,000 shares of the stock in a transaction on Friday, November 13th. The stock was purchased at an average price of $4.89 per share, for a total transaction of $391,200.00. Following the purchase, the chief executive officer directly owned 854,749 shares of the company’s stock, valued at approximately $4,179,722.61. This represents a 10.33% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is currently owned by corporate insiders.
CorMedix Company Profile
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Featured Articles
- Five stocks we like better than CorMedix
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
